Premium
Absence of Auto‐Antibodies against Cardiac Troponin I Predicts Improvement of Left Ventricular Function after Acute Myocardial Infarction
Author(s) -
Kaya Ziya,
Li Jin,
Leuschner Florian,
Göser Stefan,
Öttl Renate,
Reinhardt Lars,
Remppis Andrew,
Giannitsis Evangelos,
Katus Hugo A.
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.668.28
Subject(s) - medicine , cardiology , myocardial infarction , troponin i , clinical significance , troponin , dilated cardiomyopathy , titer , heart failure , antibody , immunology
Background: Application of antibodies (Ab) against cardiac troponin I (cTnI) can induce dilation and dysfunction of the heart in mice. But little is known about the clinical relevance of detected cTnI‐Ab. Methods: First, anti‐cTnI and anti‐cTnT Ab titers have been measured in sera from 272 patients with dilated‐ (DCM) and 185 with ischemic‐ (ICM) cardiomyopathy. Secondly, 108 patients with acute myocardial infarction (AMI) were included for a follow‐up study. All 108 patients were treated according to current guidelines. Heart characteristics were determined by magnetic resonance imaging 3–4 days and 6–9 months after AMI. Results: Altogether, in 14,3% of patients with DCM and in 17,3% with ICM an anti‐cTnI IgG‐Ab titer ≥1:80 was measured. In contrast, only in 1,8% of patients with DCM and in 0,5% with ICM an anti‐cTnT IgG‐Ab titer ≥1:80 was detected. Ten out of 108 patients included in the follow‐up study were tested positive for cTnI‐Ab with IgG Ab titers ≥1:160. TnI‐Ab negative patients showed a significant increase in LVF and stroke volume 6–9 months after AMI. In contrast, there was no significant increase in LVF and stroke volume in TnI‐Ab positive patients. Conclusion: We demonstrate for the first time that the prevalence of cTnI‐Abs in patients with AMI has an impact on the improvement of the LVF.